摘要
目的观察胸腺五肽联合甲基强的松龙对急性呼吸窘迫综合征(ARDS)患者的炎症因子水平变化及疗效的影响。方法 90例ARDS患者随机分为对照组、甲强龙组和联合治疗组,每组30例。对照组根据病情给予常规治疗;甲强龙组除了常规治疗外加用甲基强的松龙80 mg/d;联合治疗组除了常规治疗外加用胸腺五肽10 mg/d和甲基强的松龙80 mg/d;疗程均为7 d。比较3组炎症因子水平变化、急性生理与慢性健康(APACHEII)评分、氧合指数及机械通气时间等指标。结果治疗7 d后,甲强龙组与联合治疗组患者血清hs-CRP、IL-6、TNF-α水平和APACHEII评分均低于对照组(P<0.05),氧合指数高于对照组(P<0.05),机械通气时间短于对照组(P<0.05),且以联合治疗组的变化更为显著(P<0.01)。结论胸腺五肽联合甲基强的松龙治疗ARDS患者,可有效降低患者的炎症因子,提高临床疗效。
Objective To investigate the influence and curative effect of thymopentin combined with methylprednisolone on inflammatory factors of patients with acute respiratory distress syndrome（ARDS）. 90 patients with ARDS were Methodsrandomly divided into Control Group, Methylprednisolone Group and Combination Group, 30 cases in each group. The Control Group was given conventional treatment according to the disease condition; the Methylprednisolone Group was additionally administered with methylprednisolone at 80 mg/d based on the conventional treatment; the Combination Group was additionally administered with thymopentin at 10 mg/d and methylprednisolone at 80 mg/d based on the conventional treatment, and the treatment course was 7 days for all the groups. The three groups were compared in terms of the changes in the levels of inflammatory factors, Acute Physiology and Chronic Health Evaluation（APACHEⅡ） score, oxygenation index and mechanical ventilation time. Results After 7 days of treatment, the Methylprednisolone Group and Combination Group had serum hs-CRP, IL-6, TNF-α and APACHE II scores lower than the Control Group（P〈0.05）, the oxygenation index higher than the Control Group（P〈0.05） and mechanical ventilation time shorter than the Control Group（P〈0.05）, and the Combination Group showed a more significant change（P〈0.01）. Conclusion Thymopentin combined with methylprednisolone can significantly inhibit the inflammatory factors and help to improve the therapeutic effect in patients with ARDS.
作者
黄慧
李伟坚
朱伟旺
HUANG Hui;LI Wei-jian;ZHU Wei-wang(Department of Respiratory Medicine,Central People＇s Hospital of Huizhou,Huizhou 541001,China)
出处
《广东医科大学学报》
2018年第4期394-396,共3页
Journal of Guangdong Medical University
基金
惠州市科技计划项目(No.2013Y002)
关键词
急性呼吸窘迫综合征
胸腺五肽
甲基强的松龙
炎症因子
acute respiratory distress syndrome
thymopentin
methylprednisolone
inflammatory factors
